Orphan Drugs and Rare Diseases: Innovation vs. Affordability

This brief examines the economic and ethical challenges of orphan drug pricing in the United States. While the Orphan Drug Act of 1983 spurred innovation for rare diseases, it also created affordability issues and opportunities for market abuse. The paper explores policy options to balance innovation incentives with equitable access to life-saving treatments.

Published by

 on 

January 7, 2026

Inquiry-driven, this project may reflect personal views, aiming to enrich problem-related discourse.

HeadingHeading 3

Card Title

Lorem ipsum dolor sit amet conse adipiscing elit

Card Title

Lorem ipsum dolor sit amet conse adipiscing elit

Card Title

Lorem ipsum dolor sit amet conse adipiscing elit

Card Title

Lorem ipsum dolor sit amet conse adipiscing elit

Support

Storey Kuo

PIVOT Operations Intern

Storey Kuo is a student at Chadwick School who's passionate about healthcare and economic policy. At YIP, she serves as an Operations Intern for the PIVOT Center.

Author's Profile